Response to: Biosimilars for vasculitis: promise requires validation by quality studies
- 2 September 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 39 (10), 3155-3156
- https://doi.org/10.1007/s10067-020-05381-0
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Biosimilars for vasculitis: promise requires validation by quality studiesClinical Rheumatology, 2020
- Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experienceClinical Rheumatology, 2020
- Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysisBioDrugs, 2019
- FP208CLINICAL EVALUATION OF BIOSIMILAR ANTI-CD20 MONOCLONAL ANTIBODY WITH RITUXIMAB IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITISNephrology Dialysis Transplantation, 2019
- Recent advances in the management of antineutrophil cytoplasmic antibody-associated vasculitisIndian Journal of Rheumatology, 2019
- Prescribing patterns and safety of biologics in immune-mediated rheumatic diseases: Karnataka biologics cohort study group experienceIndian Journal of Rheumatology, 2019
- Clinical features and long‐term outcomes of 105 granulomatosis with polyangiitis patients: A single center experience from north IndiaInternational Journal of Rheumatic Diseases, 2017